In this section
Assorted resources on conditions connected to Cardiology.
Latest information on diseases in Dermatology.
A detailed look at conditions connected to Endocrinology.
Gastroenterology and Hepatology
In-depth material on Gastroenterology and Hepatology.
Assorted resources on conditions connected to Haematology.
A detailed look at conditions connected to Infectious Diseases.
Neurology (CNS) and Pain
Learning materials and guidelines on Neurology (CNS) and Pain.
A detailed look at conditions connected to Oncology.
In-depth material on Respiratory conditions.
Latest information on diseases in Rheumatology.
Learning materials and guidelines on Urology.
Jazz Pharmaceuticals plc along with its partner, PharmaMar announced results from the ATLANTIS Phase III multicenter, randomized, controlled study evaluating Zepzelca (lurbinectedin) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) for adult patients with small cell lung cancer (SCLC) whose disease progressed following one prior platinum-containing line.
Genmab A/S announced that Janssen Biotech, Inc. submitted a Biologics License Application (BLA) to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
BeyondSpring announced positive topline data from its PROTECTIVE-2 Phase III registrational study showing that plinabulin in combination with pegfilgrastim met the primary endpoint with statistically significant improvement in the rate of prevention of Grade 4 neutropenia in Cycle 1 (31.5% vs 13.6%, p=0.0015), as well as achieving statistical significance in all key secondary endpoints, including duration of severe neutropenia (DSN) and absolute neutrophil count (ANC) nadir.
You may be interested in...
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited. We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19.
Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors...